Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results
Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage.
Unlocking Thermo Fisher (TMO) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
How Thermo Fisher Is Riding Bioproduction and AI-Led Growth Trends
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.
Thermo Fisher Scientific Q2 Earnings Call Highlights
Thermo Fisher Scientific NYSE: TMO reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions.
Thermo Fisher Scientific Inc. (TMO) Q2 2026 Earnings Call Transcript
Thermo Fisher Scientific Inc. (TMO) Q2 2026 Earnings Call Transcript
TMO Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.
Here's What Key Metrics Tell Us About Thermo Fisher (TMO) Q2 Earnings
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher Scientific (TMO) Surpasses Q2 Earnings and Revenue Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.03 per share, beating the Zacks Consensus Estimate of $5.71 per share. This compares to earnings of $5.36 per share a year ago.
Thermo Fisher beats quarterly estimates as customer demand improves
Thermo Fisher Scientific beat Wall Street estimates for second-quarter profit and revenue on Thursday, as improving customer demand lifted sales across all its business segments.
Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?
TMO readies for second-quarter 2026 earnings, with growth expected across key segments as bioproduction, clinical research and new launches support results.
genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal
genedrive PLC (AIM:GDR, FRA:D6M) has signed a collaboration agreement with Thermo Fisher Scientific, sending its shares up 8% to 1.4p. The point-of-care pharmacogenetic testing company will develop a high-throughput laboratory test under the deal.
